Donepezil,a drug for Alzheimer’s disease,promotes oligodendrocyte generation and remyelination

	Donepezil,a drug for Alzheimer’s disease,promotes oligodendrocyte generation and remyelination
	Xue Cui 1; Yue Guo 2; Jiahui Fang 1; Changjie Shi 1; Na Suo 2; Ru Zhang 1; Xin Xie 1
刊名	中国药理学报:英文版
	2019
卷号	40.0 期号:011 页码:1386
关键词	donepezil aricept oligodendrocyte oligodendrocyte progenitor cell differentiation myelin sheaths remyelination CNS demyelinating disorders multiple sclerosis
ISSN号	1671-4083
英文摘要	Myelin sheaths play important roles in neuronal functions.In the central nervous system(CNS),the myelin is formed by oligodendrocytes(OLs),which are differentiated from oligodendrocyte precursor cells(OPCs).In CNS demyelinating disorders such as multiple sclerosis(MS),the myelin sheaths are damaged and the remyelination process is hindered.Small molecule drugs that promote OPC to OL differentiation and remyelination may provide a new way to treat these demyelinating diseases.Here we report that donepezil,an acetylcholinesterase inhibitor(AChEI)developed for the treatment of Alzheimer's disease(AD);significantly promotes OPC to OL differentiation.Interestingly,other AChEls,including huperzine A,rivastigmine,and tacrine,have no such effect indicating that donepezil's effect in promoting OPC differentiation is not dependent on the inhibition of AChE.Donepezil also facilitates the formation of myelin sheaths in OPC-DRG neuron co-culture.More interestingly,donepezil also promotes the repair of the myelin sheaths in vivo and provides significant therapeutic effect in a cuprizone-mediated demyelination animal model.Donepezil is a drug that has been used to treat AD safely for many years;our findings suggest that it might be repurposed to treat CNS demyelinating diseases such as MS by promoting OPC to OL differentiation and remyelination.
资助项目	[Ministry of Science and Technology of China] ; [Chinese Academy of Sciences] ; [National Natural Science Foundation of China]
语种	英语
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/294944]
专题	中国科学院上海药物研究所
作者单位	1.Shanghai Key Laboratory of Signaling and Disease Research,Laboratory of Receptor-based Bio-medicine,School of Life Sciences and Technology,Tongji University 2.CAS Key Laboratory of Receptor Research,the National Center for Drug Screening,Shanghai Institute of Materia Medica,Chinese Academy of Sciences 3.中国科学院大学 4.Stake Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences
推荐引用方式 GB/T 7714	Xue Cui,Yue Guo,Jiahui Fang,et al. Donepezil,a drug for Alzheimer’s disease,promotes oligodendrocyte generation and remyelination[J]. 中国药理学报:英文版,2019,40.0(011):1386.
APA	Xue Cui.,Yue Guo.,Jiahui Fang.,Changjie Shi.,Na Suo.,...&Xin Xie.(2019).Donepezil,a drug for Alzheimer’s disease,promotes oligodendrocyte generation and remyelination.中国药理学报:英文版,40.0(011),1386.
MLA	Xue Cui,et al."Donepezil,a drug for Alzheimer’s disease,promotes oligodendrocyte generation and remyelination".中国药理学报:英文版 40.0.011(2019):1386.